<DOC>
	<DOCNO>NCT00025558</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation bone marrow transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase I trial study effectiveness combine temozolomide , thiotepa , carboplatin follow peripheral stem cell transplantation bone marrow transplantation treat patient brain cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Peripheral Stem Cell Transplantation Bone Marrow Transplantation Treating Patients With Brain Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose temozolomide combination thiotepa carboplatin follow autologous peripheral blood stem cell bone marrow transplantation patient recurrent high-grade brain tumor minimal residual disease newly-diagnosed malignant glioma minimal residual disease follow irradiation . OUTLINE : This dose-escalation study temozolomide . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily 3 consecutive day . After third dose G-CSF , patient undergo leukapheresis collect peripheral blood stem cell ( PBSC ) . Patients adequate PBSC may undergo bone marrow harvest . Patients receive oral temozolomide every 12 hour day -10 -6 thiotepa IV 3 hour carboplatin IV 4 hour day -5 -3 . PBSC bone marrow reinfused day 0 . Beginning day 1 , patient receive G-CSF SC IV blood count recover . Cohorts 3-6 patient receive escalate dos temozolomide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow day 42 , 3 month , every 3 month 2 year , every 4 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 18-30 patient accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one follow malignant brain tumor : Anaplastic astrocytoma Glioblastoma multiforme Anaplastic oligodendroglioma Medulloblastoma Highgrade ependymoma Germ cell tumor Pineoblastoma Other primitive neuroectodermal tumor Recurrent disease resistant conventional therapy ( e.g. , surgery , radiotherapy , standard chemotherapy ) No prior myeloablative dos thiotepa OR Newly diagnose malignant glioma minimal residual disease prior radiotherapy Minimal residual disease define tumor maximum diameter le 1.5 cm MRI corticosteroid dependency PATIENT CHARACTERISTICS : Age : Over 1 50 Performance status : Karnofsky 70100 % OR Lansky 70100 % Life expectancy : More 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL ( transfusion allow ) Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT/SGPT le 2.5 time ULN Alkaline phosphatase less 2.5 time ULN Renal : Creatinine le 1.5 time ULN Creatinine clearance least 70 mL/min BUN less 1.5 time ULN Cardiovascular : Ejection fraction great 50 % OR Shortening fraction great 27 % No evidence myocardial ischemia EKG 40 year age Other : HIV negative No AIDSrelated illness No frequent vomit medical condition would preclude oral medication ( e.g. , partial bowel obstruction ) No malignancy within past 2 year except surgically cure carcinoma situ cervix basal cell squamous cell skin cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 2 week since prior biologic therapy immunotherapy Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics At least 6 week since prior radiotherapy recover At least 6 week since prior brachytherapy radiosurgery Surgery : See Disease Characteristics Recovered prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
	<keyword>adult pineoblastoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult supratentorial primitive neuroectodermal tumor ( PNET )</keyword>
</DOC>